Role of Orexin Antagonists in Benzodiazepine Withdrawal

Introduction to Orexin Antagonists

Orexin receptor antagonists like suvorexant are not currently indicated for managing benzodiazepine withdrawal symptoms, though they may have potential utility as adjunctive therapy during benzodiazepine tapering due to their distinct mechanism of action and favorable safety profile 1, 2, 3

Current benzodiazepine tapering guidelines do not specifically recommend orexin antagonists as adjunctive therapy 4, 5, 6
Mayo Clinic guidelines for benzodiazepine discontinuation recommend considering alternative pharmacological treatments during tapering, but specifically mention antidepressants, cognitive-behavioral therapy, and integrative strategies rather than orexin antagonists 4, 7
A Cochrane review investigating adjunctive pharmacological interventions for benzodiazepine tapering mentioned carbamazepine, pregabalin, paroxetine, and other medications, but did not include orexin antagonists 4, 6

FDA labeling for suvorexant warns of potential cognitive and behavioral changes, including amnesia, anxiety, hallucinations, and other neuropsychiatric symptoms 1, 2
Suvorexant may cause complex behaviors such as sleep driving, worsening of depression including suicidal thinking, daytime impairments, sleep paralysis, and hypnagogic/hypnopompic hallucinations 1, 2, 3
The most common adverse effect of suvorexant is somnolence (7% vs 3% for placebo) 1, 2

The primary approach to benzodiazepine withdrawal should be a gradual taper of the benzodiazepine itself, with a reduction of approximately 25% of the daily dose every 1-2 weeks 8
Patient education about benzodiazepine risks and benefits of tapering is essential for successful discontinuation 4, 8
Non-pharmacological interventions should be incorporated, including cognitive-behavioral therapy, relaxation techniques, and physical activity 4, 6, 7
If adjunctive pharmacotherapy is needed for insomnia during withdrawal, traditional options with more evidence include trazodone, although evidence is limited 9

There is insufficient direct evidence specifically evaluating orexin antagonists in benzodiazepine withdrawal management 1, 9
Current guidelines still recommend gradual tapering of benzodiazepines with established adjunctive therapies and non-pharmacological approaches as the primary strategy 4, 7, 8